Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -197,614 | -36,240 | -88,185 | -86,652 | -16,788 |
| Depreciation Amortization | 2,972 | 4,710 | 3,835 | 1,773 | 121 |
| Accounts payable and accrued liabilities | 1,033 | -526 | 207 | 161 | 1,678 |
| Other Working Capital | 2,922 | 62,891 | 3,305 | 4,737 | 426 |
| Other Operating Activity | 39,111 | 19,281 | 4,203 | 8,073 | -489 |
| Operating Cash Flow | $-151,576 | $50,116 | $-76,635 | $-71,908 | $-15,052 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -17,919 | -3,393 | -2,875 | -6,134 | -3,062 |
| Purchase Of Investment | -369,696 | -557,930 | -179,789 | -226,870 | N/A |
| Sale Of Investment | 535,327 | 273,901 | 141,498 | 14,000 | N/A |
| Investing Cash Flow | $147,712 | $-287,422 | $-41,166 | $-219,004 | $-3,062 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 5,000 |
| Common Stock Issued | 6,190 | 98,405 | 266,352 | 111 | 620 |
| Other Financing Activity | 0 | -1,386 | 29,971 | 300,365 | 43,234 |
| Financing Cash Flow | $6,190 | $97,019 | $296,323 | $300,476 | $48,854 |
| Beginning Cash Position | 78,623 | 218,910 | 40,388 | 30,824 | N/A |
| End Cash Position | 80,949 | 78,623 | 218,910 | 40,388 | 30,740 |
| Net Cash Flow | $2,326 | $-140,287 | $178,522 | $9,564 | $30,740 |
| Free Cash Flow | |||||
| Operating Cash Flow | -151,576 | 50,116 | -76,635 | -71,908 | -15,052 |
| Capital Expenditure | -17,919 | -3,393 | -2,875 | -6,134 | -3,062 |
| Free Cash Flow | -169,495 | 46,723 | -79,510 | -78,042 | -18,114 |